Biotest AG
Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest’s antibody-drug conjugate (BT-062)
DGAP-News: Biotest AG / Key word(s): Alliance PRESS RELEASE ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest’s antibody-drug conjugate (BT-062) – License agreement with ImmunoGen will continue
ImmunoGen notified Biotest that they have elected not to exercise a late stage co-development option provided for in the cooperation agreement. For a payment of USD 15 million, ImmunoGen would have opted in to share half of the development and marketing of Indatuximab Ravtansine (BT-062) in the US market. The license agreement with ImmunoGen regarding the use of its linker and payload technology continues unchanged. The Phase I/IIa study (Study 983) is investigating Indatuximab Ravtansine (BT-062) in combination with lenalidomide or pomalidomide and dexamethasone in patients with multiple myeloma who have not been responding (any more) to previous treatments. Multiple myeloma is a malignant hematologic disease and despite new treatment options patients very often relapse. Biotest presented new clinical data derived from an ongoing combination study with BT-062 in December 2016 at the annual meeting of the American Society of Hematology (ASH). A phase I/II study (study 989) with Indatuximab Ravtansine (BT-062) for the treatment of solid tumors (breast cancer and bladder cancer) is currently being evaluated. About Indatuximab Ravtansine (BT-062) About Biotest IR contact Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Disclaimer
24.03.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 – 8 01-0 |
Fax: | 0 61 03 – 8 01-150 |
E-mail: | investor_relations@biotest.de |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |